Joint Formulary & PAD

Formulary Search

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Search

A-Z of Drugs : A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

A-Z of Drugs

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

A to Z of Drugs : R

Records returned : 98 (on 16 Jul 2025 at 20:18:09).

Show Icon and Status Keys

Drug
Indication
Status
Restrictions/Comments
Formulary Status
Links
Status :
Green (see narrative)
Formulations :
  • Tablets
Restrictions / Comments:

Important
2nd line in adults without swallowing difficulties. (Suitable for patients that cannot have animal-derived products / capsules.)
 
Links :
Indication :
Status :
Formulations :
  • Not Specified
Restrictions / Comments:

 
Links :
SPC
Indication :
Status :
Non Formulary
Formulations :
  • Not Specified
Restrictions / Comments:

 
Links :
NFD1
SPC
Status :
Blue
Formulations :
  • Tablets
Restrictions / Comments:

Important

Off-label use. Specialist initiation and prescribing for at least 1 month before any request is made for primary care prescribing.

 
Links :
NICE
Off Label
SPC
Indication :
Status :
Green (see narrative)
Formulations :
  • Tablets
Restrictions / Comments:

Important

Only recommended as an option in secondary prevention where other options have been exhausted.

 
Links :
Status :
Red
Formulations :
  • Tablets
Restrictions / Comments:

Important

For post-exposure prophylaxis (e.g. needlestick injuries), follow your organisation's protocols for referral and access. Use as recommended by BHIVA/BASHH guidelines.

 
Links :
NHSE
R
SPC
Indication :
Status :
Green
Formulations :
  • Capsules
Restrictions / Comments:

Preferred
 
Links :
Indication :
Status :
Green
Formulations :
  • Capsules
Restrictions / Comments:

Important
Preferred
Use an ARB where possible. If an ACEi is required (patient with heart failure or post MI), ramipril is the preferred option.
 
Links :
Status :
Red
Formulations :
  • Intravitreal injection
Restrictions / Comments:

 
Links :
ICB
NICE
SPC
Status :
Red
Formulations :
  • Intravitreal injection
Restrictions / Comments:

 
Links :
ICB
NICE
SPC
Indication :
Status :
Red
Formulations :
  • Intravitreal injection
Restrictions / Comments:

 
Links :
Status :
Red
Formulations :
  • Intravitreal injection
Restrictions / Comments:

 
Links :
ICB
NICE
SPC
Status :
Non Formulary
Formulations :
  • Not Specified
Restrictions / Comments:

 
Links :
Indication :
Status :
Amber
Formulations :
  • Modified release tablets
Restrictions / Comments:

Important
Restricted to cardiology
 
Links :
SPC
Status :
Non Formulary
Formulations :
  • Not Specified
Restrictions / Comments:

 
Links :
NFD1
SPC
Indication :
Status :
Blue
Formulations :
  • Tablets
Restrictions / Comments:

 
Links :
SPC
Status :
Red
Formulations :
  • Intravenous infusion
Restrictions / Comments:

 
Links :
NHSE
SPC
Indication :
Status :
Red
Formulations :
  • Not Specified
Restrictions / Comments:

 
Links :
SPC
Indication :
Status :
Blue
Formulations :
  • Tablets
Restrictions / Comments:

Important

Specialist to prescribe at least 1 month treatment, prior to transfer of care

 
Links :
Indication :
Status :
See narrative
Formulations :
  • Tablets
Restrictions / Comments:

Important

Not assessed for formulary status. An application to APC is required.

 
Links :
NFD2
SPC
Indication :
Status :
Blue
Formulations :
  • Tablets
Restrictions / Comments:

Important

Specialist team initiation and at least 3 months of treatment prior to any request for primary care prescribing.

A DXA scan is recommended after the first 52 weeks of treatment 

 

 

 
Links :
Indication :
Status :
Red
Formulations :
  • Intravenous infusion
Restrictions / Comments:

 
Links :
23. Renamil
Drug:
Renamil
(Condition specific ONS )
Status :
Blue
Formulations :
  • Powder
Restrictions / Comments:

Important

Prescribe on advice from specialist e.g. dietitian 

 
Links :
24. Renapro Powder
Drug:
Renapro Powder
(Condition specific ONS )
Status :
Blue
Formulations :
  • Powder
Restrictions / Comments:

Important

Prescribe on advice from specialist e.g. dietitian 

 
Links :
25. Renapro Shot
Drug:
Renapro Shot
(Condition specific ONS )
Status :
Blue
Formulations :
  • Liquid
Restrictions / Comments:

Important

Prescribe on advice from specialist e.g. dietitian 

 
Links :
26. Renastart
Drug:
Renastart
(Condition specific ONS )
Status :
Blue
Formulations :
  • Powder
Restrictions / Comments:

Important

Prescribe on advice from specialist e.g. dietitian 

 
Links :
Indication :
Status :
Blue
Formulations :
  • Tablets
Restrictions / Comments:

Important

On advice from specialist.  

NHSE do not recommend the routine prescription of vitamins and mineral preparations, with the exceptions of patients with medically diagnosed deficiency, including those with lifelong or chronic conditions, or post surgery resulting in malabsorption (e.g.  Whipple’s procedure and some other GI surgeries), calcium and vitamin D for osteoporosis, prescription-only vitamin D analogues or malnutrition. Continuing need should be reviewed on a regular basis. Not for use for prevention of deficiency  

 
Links :
SPC
28. Renilon 7.5
Drug:
Renilon 7.5
(Condition specific ONS )
Status :
Blue
Formulations :
  • Liquid
Restrictions / Comments:

Important

Prescribe on advice from specialist e.g. dietitian 

 
Links :
29. Repaglinide
Drug:
Repaglinide
(Antidiabetic drugs)
Indication :
Status :
Green
Formulations :
  • Tablets
Restrictions / Comments:

 
Links :
Status :
Red
Formulations :
  • Not Specified
Restrictions / Comments:

Important
Service not currently provided by any Surrey Heartlands Trusts
 
Links :
NHSE
NICE
SPC
Indication :
Status :
Non Formulary
Formulations :
  • Liquid
Restrictions / Comments:

 
Links :
32. Resource Energy
Drug:
Resource Energy
(Milkshake style ONS)
Indication :
Status :
Non Formulary
Formulations :
  • Liquid
Restrictions / Comments:

Important

Altraplen Energy is the preferred second line 1.5kcal/ml supplement when required in primary care. Ready to drink supplements should only be prescribed if individual cannot prepare milkshake from powder.

 
Links :
Indication :
Status :
Green
Formulations :
  • Powder
Restrictions / Comments:

Preferred
 
Links :
Indication :
Status :
Red
Formulations :
  • Capsules
  • Injection
  • Oral solution
  • Tablets
Restrictions / Comments:

 
Links :
NHSE
SPC
Indication :
Status :
Red
Formulations :
  • Not Specified
Restrictions / Comments:

 
Links :
SPC
Indication :
Status :
Red
Formulations :
  • Capsules
Restrictions / Comments:

Important
Restricted Use - requires microbiology or respiratory approval
 
Links :
R
SPC
Indication :
Status :
Red
Restrictions / Comments:

Important
Restricted use of injection with bone pate by ENT to reduce infection of autologous bone pate in mastoid obliteration surgery.
 
Links :
R
SPC
Indication :
Status :
Red
Formulations :
  • Not Specified
Restrictions / Comments:

Important
Liaise with Chest Physician. Patients with multi-drug resistant TB should be treated by a specialist centre.
 
Links :
R
SPC
Indication :
Status :
Red
Formulations :
  • Tablets
Restrictions / Comments:

Important
Liaise with Chest Physician. Patients with multi-drug resistant TB should be treated by a specialist centre.
 
Links :
R
SPC
Indication :
Status :
Red
Formulations :
  • Tablets
Restrictions / Comments:

Important
Liaise with Chest Physician. Patients with multi-drug resistant TB should be treated by a specialist centre.
 
Links :
R
SPC
Indication :
Status :
Red
Formulations :
  • Tablets
Restrictions / Comments:

Important
Liaise with Chest Physician. Patients with multi-drug resistant TB should be treated by a specialist centre.
 
Links :
R
SPC
Indication :
Status :
Non Formulary
Formulations :
  • Not Specified
Restrictions / Comments:

Important
STAND-BY or PREVENTATIVE treatment is not currently recommended in the NHS Surrey Management of Infection Guidelines. it is difficult for travellers to distinguish between invasive and non-invasive diarrhoea, the overall usefulness of rifaximin as empiric self-treatment remains to be determined. Stand-by treatment of this nature should not be prescribed on the NHS but a private prescription may be issued if appropriate
 
Links :
NFD1
SPC
Indication :
Status :
Blue
Formulations :
  • Tablets
Restrictions / Comments:

Important
Restricted use on recommendation of Gastroenterology consultants for treatment of hepatic encephalopathy.
 
Links :
R
SPC
Indication :
Status :
Amber
Formulations :
  • Oral suspension
  • Orodispersible films
  • Tablets
Restrictions / Comments:

 
Links :
Indication :
Status :
Green
Formulations :
  • Oral lyophilisates
Restrictions / Comments:

 
Links :
Indication :
Status :
Red
Formulations :
  • Oral lyophilisates
Restrictions / Comments:

Important
For episodic migraine only
 
Links :
Status :
Non Formulary
Formulations :
  • Not Specified
Restrictions / Comments:

Important

NHSE commissioned services only. No Surrey Heartlands Trusts are commissioned to provide this.

 
Links :
NFD1
NHSE
SPC
Status :
Red
Formulations :
  • Intravenous infusion
  • Subcutaneous injection (sc)
Restrictions / Comments:

Important
For UC & CD. Adults only
 
Links :
Indication :
Status :
Red
Formulations :
  • Not Specified
Restrictions / Comments:

 
Links :
ICB
NICE
SPC
Indication :
Status :
Red
Formulations :
  • Subcutaneous injection (sc)
Restrictions / Comments:

 
Links :
ICB
NICE
SPC
Indication :
Status :
Green
Formulations :
  • Tablets
Restrictions / Comments:

Important
Preferred

Weekly tablets are 35mg. Daily tablets are 5mg.
NOTE - 30mg tablets are licensed for Paget's disease only

 
Links :
Indication :
Status :
Red
Formulations :
  • Tablets
Restrictions / Comments:

Important

30mg tablets are licensed for Paget's disease.

 
Links :
SPC
Status :
Green (see narrative)
Formulations :
  • Oral solution
  • Tablets
Restrictions / Comments:

Important

Licensed for up to 6 weeks in Alzheimer's dementia. On initiation, patients need a referal to SABP so that an assessment can be made at 6 weeks to weigh up response to treatment and benefit of treatment v risk of harm.

 
Links :
Status :
Red
Formulations :
  • Oro-dispersible tablets
Restrictions / Comments:

Important

Licensed for up to 6 weeks in Alzheimer's dementia. On initiation, patients need a referal to SABP so that an assessment can be made at 6 weeks to weigh up response to treatment and benefit of treatment v risk of harm.

Only for use where the liquid formulation is unsuitable e.g. for supervised administration to ensure compliance.

 
Links :
Status :
Blue
Formulations :
  • Tablets
Restrictions / Comments:

Important

Primary Care prescribing on advice from palliative care specialist team

 
Links :
Off Label
SPC
Indication :
Status :
Blue
Formulations :
  • Oral solution
  • Tablets
Restrictions / Comments:

Important

Initiation by a SABP specialist and stabilisation for a minimum of 3 months before any request to transfer prescribing responsibility.

 
Links :
Indication :
Status :
Red
Formulations :
  • Oro-dispersible tablets
Restrictions / Comments:

Important

Initiation by a SABP specialist and stabilisation for a minimum of 3 months before any request to transfer prescribing responsibility.

Only for use where the liquid formulation is unsuitable e.g. for supervised administration to ensure compliance.

 
Links :
R
SPC
Indication :
Status :
Blue
Formulations :
  • Oral solution
  • Tablets
Restrictions / Comments:

Important

Initiation by a SABP specialist and stabilisation for a minimum of 3 months before any request to transfer prescribing responsibility.

 
Links :
Indication :
Status :
Red
Formulations :
  • Oro-dispersible tablets
Restrictions / Comments:

Important

Initiation by a SABP specialist and stabilisation for a minimum of 3 months before any request to transfer prescribing responsibility.

Only for use where the liquid formulation is unsuitable e.g. for supervised administration to ensure compliance.

 
Links :
R
SPC
Indication :
Status :
Red
Formulations :
  • Capsules
Restrictions / Comments:

 
Links :
ICB
NICE
SPC
Indication :
Status :
Red
Formulations :
  • Tablets
Restrictions / Comments:

Important
Restricted Antimicrobial - requires GUM Specialist approval
 
Links :
NHSE
R
SPC
Status :
Red
Formulations :
  • Not Specified
Restrictions / Comments:

Important
Specialist centres only
 
Links :
NHSE
SPC
Indication :
Status :
Red
Formulations :
  • Not Specified
Restrictions / Comments:

Important
Specialist centres only
 
Links :
NHSE
SPC
Status :
Red
Formulations :
  • Not Specified
Restrictions / Comments:

Important
Specialist centres only
 
Links :
NHSE
SPC
Status :
Red
Formulations :
  • Not Specified
Restrictions / Comments:

Important
Specialist centres only
 
Links :
NHSE
SPC
Status :
Red
Formulations :
  • Not Specified
Restrictions / Comments:

Important
Specialist centres only
 
Links :
NHSE
SPC
Status :
Red
Formulations :
  • Injection
Restrictions / Comments:

 
Links :
Guidelines
ICB
Off Label
SPC
Status :
Red
Formulations :
  • Not Specified
Restrictions / Comments:

Important
Specialist centres only
 
Links :
NHSE
SPC
Indication :
Status :
Red
Formulations :
  • Not Specified
Restrictions / Comments:

Important
Specialist centres only
 
Links :
NHSE
SPC
Indication :
Status :
Red
Formulations :
  • Not Specified
Restrictions / Comments:

 
Links :
NHSE
SPC
Indication :
Status :
Red
Formulations :
  • Intravenous infusion
Restrictions / Comments:

Important
Severe disease only
 
Links :
Indication :
Status :
Red
Formulations :
  • Not Specified
Restrictions / Comments:

Important
Specialist centres only
 
Links :
NHSE
SPC
Status :
Red
Formulations :
  • Not Specified
Restrictions / Comments:

Important
Specialist centres only
 
Links :
NHSE
SPC
Indication :
Status :
Green (see narrative)
Formulations :
  • Tablets
Restrictions / Comments:

 
Links :
Status :
Blue
Formulations :
  • Tablets
Restrictions / Comments:

Important
Specialist initiation and at least one month supply before transfer to primary care
 
Links :
Status :
Blue
Formulations :
  • Tablets
Restrictions / Comments:

Important
Specialist initiation and at least one month supply before transfer to primary care
 
Links :
Status :
Green
Formulations :
  • Tablets
Restrictions / Comments:

 
Links :
Status :
Red
Formulations :
  • Tablets
Restrictions / Comments:

 
Links :
SPC
Indication :
Status :
Blue
Formulations :
  • Capsules
  • Patches
Restrictions / Comments:

Important

Rivastigmine is BLUE (with information sheet) for those patients who are stable and suitable for discharge from specialist care.

This entry has not yet been reviewed for inclusion on the joint formulary. However, this information has been published due to the ongoing requirement for prescribers to access the shared care agreement and other resources that were in place prior to the launch of the joint formulary.

 
Links :
Indication :
Status :
Amber
Formulations :
  • Capsules
  • Patches
Restrictions / Comments:

Important

AMBER shared care applies for patients that are not suitable for discharge and who will continue to receive follow up by SABP.

This entry has not yet been reviewed for inclusion on the joint formulary. However, this information has been published due to the ongoing requirement for prescribers to access the shared care agreement and other resources that were in place prior to the launch of the joint formulary.

 
Links :
Indication :
Status :
Non Formulary
Formulations :
  • Not Specified
Restrictions / Comments:

 
Links :
NFD1
SPC
Indication :
Status :
Green
Formulations :
  • Tablets
Restrictions / Comments:

Important
Preferred
Prescribe generically
 
Links :
SPC
Indication :
Status :
Green (see narrative)
Formulations :
  • Oro-dispersible tablets
Restrictions / Comments:

Important
Prescribe generically
Prescribe as generic orodispersible tablets (NOT oral lyophilisates). For use in patients with swallowing difficulties, nausea or vomitting.
 
Links :
R
SPC
Indication :
Status :
Non Formulary
Formulations :
  • Oral lyophilisates
Restrictions / Comments:

Important
Prescribe generically
Prescribe as orodispersible tablets
 
Links :
NFD1
SPC
Status :
Blue
Formulations :
  • Tablets
Restrictions / Comments:

Important
Restricted to initiation by respiratory specialists in line with NICE TA461. https://www.gov.uk/drug-safety-update/roflumilast-daxas-risk-of-suicidal-behaviour
 
Links :
Status :
Red
Formulations :
  • Subcutaneous injection (sc)
Restrictions / Comments:

Important

Haematology use only - treating chronic immune thrombocytopenia as per NICE TA221.

 
Links :
Indication :
Status :
Red
Formulations :
  • Injection
Restrictions / Comments:

 
Links :
Indication :
Status :
Green
Formulations :
  • Immediate release tablets
Restrictions / Comments:

Important
Preferred
Patients with severe symptoms, who are obese, co-morbid depression, increased risk of falls or cognitive impairment
 
Links :
SPC
Indication :
Status :
Blue
Formulations :
  • Tablets
Restrictions / Comments:

 
Links :
Indication :
Status :
Blue
Formulations :
  • Modified release tablets
Restrictions / Comments:

 
Links :
Status :
Non Formulary
Formulations :
  • Not Specified
Restrictions / Comments:

 
Links :
NFD1
SPC
Indication :
Status :
Green
Formulations :
  • Tablets
Restrictions / Comments:

 
Links :
Indication :
Status :
Blue
Formulations :
  • Patches
Restrictions / Comments:

Important
Consider patches if levodopa and / or oral dopamine are not effective in treating nocturnal akinesia
 
Links :
Indication :
Status :
Green
Formulations :
  • Patches
Restrictions / Comments:

Important
Preferred
Patients with severe symptoms, who are obese, co-morbid depression, increased risk of falls or cognitive impairment. Consider use of patch if significant daytime symptoms as it has a long duration of action.
 
Links :
SPC
Indication :
Status :
Red
Formulations :
  • Tablets
Restrictions / Comments:

Important

Renal specialist teams only.

 
Links :
ICB
NICE
SPC
Indication :
Status :
Amber
Formulations :
  • Tablets
Restrictions / Comments:

Important
SASH - restricted to paediatrics only. RSCH - only initiate on recommendation from a tertiary referral centre.
 
Links :
R
SPC
Indication :
Status :
Amber
Formulations :
  • Oral suspension
Restrictions / Comments:

Important
RSCH - only initiate on recommendation from a tertiary referral centre.
 
Links :
R
SPC
Indication :
Status :
Non Formulary
Formulations :
  • Not Specified
Restrictions / Comments:

 
Links :